Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants - Concepedia

Concepedia

Publication | Open Access

Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants

DOI Full Paper Access

222

Citations

22

References

2018

Year

Joseph B. Domachowske, Anis A. Khan, Mark T. Esser, Kathryn Jensen, Therese Takas, Tonya Villafana, Filip Dubovsky, M. Pamela Griffin

The Pediatric Infectious Disease Journal

Abstract

MEDI8897 had a favorable safety profile in healthy preterm infants. The extended half-life of MEDI8897 and demonstrated RSV-neutralizing activity support protection from RSV for the duration of a typical 5-month season after a single 50 mg intramuscular (IM) dose.

References

	Year	Citations

Page 1